Akamis Bio Highlights Data Showing Potential of its Adenovirus Vector Technology in Combination with Radiation to Treat Advanced Rectal Cancer
CAMBRIDGE, Mass. & OXFORD, England--(BUSINESS WIRE)--Akamis Bio, a clinical-stage oncology company using a proprietary Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to deliver novel immunotherapeutic proteins, biomolecules and transgene combinations to treat solid tumors, today announced the appointment of Oliver Rosen, M.D. as Chief Medical Officer (CMO), Peter Kosa, Ph.D. as Chief Business Officer (CBO), and Samantha Bailey-Bucktrout, Ph.D. as Senior Vice President, Head of Research. Drs. Rosen and Kosa will be based in the Company’s Cambridge, MA office and Dr. Bailey-Bucktrout will continue to lead Research from the Oxford, UK site.
Akamis Bio is expanding its collaboration with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical partnership with the Cancer Research Institute (CRI) for advancing new pancreatic cancer treatments.
OXFORD, England - ( BUSINESS WIRE ) - PsiOxus Therapeutics, Ltd. . (PsiOxus), a tumor reprogramming company, today announces that it will present key safety and translational data from its first FORTITUDE phase 1 human clinical study at the 2021 European Society of Oncology Congress (ESMO) , this week. Data from the completed dose-escalation monotherapy portion of the FORTITUDE study, launched in 2019 to assess the safety and tolerability of the NG-350A T-SIGn ® vector , will be presented on Friday, September 16, 2021. The poster will be available in full at www.psioxus.com shortly thereafter.
OXFORD, England & CAMBRIDGE, Mass.--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus), a clinical stage oncology company ?re-programming ?the tumor microenvironment to overcome the central challenge of resistance to therapy, and bluebird bio, Inc. (Nasdaq: BLUE) presented preclinical data at the American Association for Cancer Research (AACR) Annual Meeting 2021. The study, “T-SIGn cancer gene therapy and anti-EGFR CAR-T cells synergize in combination therapy to clear A549 lung tumor xenografts”, assessed anti-tumor synergy between PsiOxus’ T-SIGn® vectors and an anti-epidermal growth factor receptor (EGFR) chimeric antigen receptor (CAR)-T cell therapy from bluebird bio in xenograft lung tumors.
Bristol Myers Squibb and PsiOxus Therapeutics are expanding their partnership—again. The duo first teamed up in June 2016 to study the latter’s cancer-killing virus, inking a deal later that year to combine the virus with BMS’ checkpoint inhibitor, Opdivo. Now, they’re adding a second asset from PsiOxus to the mix.
OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) to treat a range of tumor types in late-stage cancer patients.
OXFORD, England--(BUSINESS WIRE)--PsiOxus Therapeutics, Ltd. (PsiOxus) today announced an updated agreement to advance its clinical collaboration with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ tumor re-engineering platform, in combination with Bristol Myers Squibb’s PD-1 immune checkpoint inhibitor Opdivo® (nivolumab) to treat a range of tumor types in late-stage cancer patients.